Chemerin and prediction of Diabetes mellitus type 2
Corresponding Author
Thomas Bobbert
Department of Endocrinology, Diabetes and Nutrition, Charité-Universitätsmedizin Berlin, Berlin, Germany
Correspondence: Thomas Bobbert, Charité, Department of Endocrinology, Diabetes and Nutrition, Charitéplatz 1, 10117 Berlin, Germany. Tel.:+49/30/450-514252; Fax: +49/30/450-514950; E-mail: [email protected]Search for more papers by this authorFranziska Schwarz
Department of Endocrinology, Diabetes and Nutrition, Charité-Universitätsmedizin Berlin, Berlin, Germany
Charité Center for cardiovascular Research (CCR), Charité-Universitätsmedizin Berlin, Berlin, Germany
Search for more papers by this authorAntje Fischer-Rosinsky
Department of Endocrinology, Diabetes and Nutrition, Charité-Universitätsmedizin Berlin, Berlin, Germany
Charité Center for cardiovascular Research (CCR), Charité-Universitätsmedizin Berlin, Berlin, Germany
Experimental and Clinical Research Center, Charité-Universitätsmedizin Berlin and Max-Delbrück Zentrum, Berlin-Buch, Germany
Search for more papers by this authorLukas Maurer
Department of Endocrinology, Diabetes and Nutrition, Charité-Universitätsmedizin Berlin, Berlin, Germany
Charité Center for cardiovascular Research (CCR), Charité-Universitätsmedizin Berlin, Berlin, Germany
Experimental and Clinical Research Center, Charité-Universitätsmedizin Berlin and Max-Delbrück Zentrum, Berlin-Buch, Germany
Search for more papers by this authorMatthias Möhlig
Department of Endocrinology, Diabetes and Nutrition, Charité-Universitätsmedizin Berlin, Berlin, Germany
Search for more papers by this authorA.F.H. Pfeiffer
Department of Endocrinology, Diabetes and Nutrition, Charité-Universitätsmedizin Berlin, Berlin, Germany
Department of Clinical Nutrition, German Institute of Human Nutrition, Nuthetal, Germany
Search for more papers by this authorKnut Mai
Department of Endocrinology, Diabetes and Nutrition, Charité-Universitätsmedizin Berlin, Berlin, Germany
Experimental and Clinical Research Center, Charité-Universitätsmedizin Berlin and Max-Delbrück Zentrum, Berlin-Buch, Germany
Search for more papers by this authorJoachim Spranger
Department of Endocrinology, Diabetes and Nutrition, Charité-Universitätsmedizin Berlin, Berlin, Germany
Charité Center for cardiovascular Research (CCR), Charité-Universitätsmedizin Berlin, Berlin, Germany
Experimental and Clinical Research Center, Charité-Universitätsmedizin Berlin and Max-Delbrück Zentrum, Berlin-Buch, Germany
Search for more papers by this authorCorresponding Author
Thomas Bobbert
Department of Endocrinology, Diabetes and Nutrition, Charité-Universitätsmedizin Berlin, Berlin, Germany
Correspondence: Thomas Bobbert, Charité, Department of Endocrinology, Diabetes and Nutrition, Charitéplatz 1, 10117 Berlin, Germany. Tel.:+49/30/450-514252; Fax: +49/30/450-514950; E-mail: [email protected]Search for more papers by this authorFranziska Schwarz
Department of Endocrinology, Diabetes and Nutrition, Charité-Universitätsmedizin Berlin, Berlin, Germany
Charité Center for cardiovascular Research (CCR), Charité-Universitätsmedizin Berlin, Berlin, Germany
Search for more papers by this authorAntje Fischer-Rosinsky
Department of Endocrinology, Diabetes and Nutrition, Charité-Universitätsmedizin Berlin, Berlin, Germany
Charité Center for cardiovascular Research (CCR), Charité-Universitätsmedizin Berlin, Berlin, Germany
Experimental and Clinical Research Center, Charité-Universitätsmedizin Berlin and Max-Delbrück Zentrum, Berlin-Buch, Germany
Search for more papers by this authorLukas Maurer
Department of Endocrinology, Diabetes and Nutrition, Charité-Universitätsmedizin Berlin, Berlin, Germany
Charité Center for cardiovascular Research (CCR), Charité-Universitätsmedizin Berlin, Berlin, Germany
Experimental and Clinical Research Center, Charité-Universitätsmedizin Berlin and Max-Delbrück Zentrum, Berlin-Buch, Germany
Search for more papers by this authorMatthias Möhlig
Department of Endocrinology, Diabetes and Nutrition, Charité-Universitätsmedizin Berlin, Berlin, Germany
Search for more papers by this authorA.F.H. Pfeiffer
Department of Endocrinology, Diabetes and Nutrition, Charité-Universitätsmedizin Berlin, Berlin, Germany
Department of Clinical Nutrition, German Institute of Human Nutrition, Nuthetal, Germany
Search for more papers by this authorKnut Mai
Department of Endocrinology, Diabetes and Nutrition, Charité-Universitätsmedizin Berlin, Berlin, Germany
Experimental and Clinical Research Center, Charité-Universitätsmedizin Berlin and Max-Delbrück Zentrum, Berlin-Buch, Germany
Search for more papers by this authorJoachim Spranger
Department of Endocrinology, Diabetes and Nutrition, Charité-Universitätsmedizin Berlin, Berlin, Germany
Charité Center for cardiovascular Research (CCR), Charité-Universitätsmedizin Berlin, Berlin, Germany
Experimental and Clinical Research Center, Charité-Universitätsmedizin Berlin and Max-Delbrück Zentrum, Berlin-Buch, Germany
Search for more papers by this authorSummary
Objective
Insulin resistance and subclinical inflammation are characteristics in the development of type 2 diabetes mellitus (T2DM). The adipokine chemerin has been associated with both factors. The aim of this study was to analyse whether chemerin predicts T2DM.
Design
Blood samples of 440 participants of the Metabolic-Syndrome Berlin-Potsdam (MesyBepo) follow-up study without diabetes at baseline were available for chemerin measurement. Mean follow-up of participants was 5·3 years. Glucose metabolism was analysed using oral glucose tolerance test including insulin measurements. Chemerin was measured using a commercially available ELISA.
Results
Thirty-five individuals developed T2DM during follow-up. Chemerin predicted incident T2DM (Chemerin 1. Tertile: reference, 2. Tertile: OR 2·33 [0·68–7·95]; Chemerin 3. Tertile: OR 3·42 [1·01–11·58] after adjustment for age, sex, BMI, follow-up time, HbA1c, HOMA-IR and WHR). In a secondary analysis, chemerin also predicted worsening of fasting glucose and HbA1c (adjusted for age, sex, BMI, time of follow-up, WHR, HDL cholesterol and triglycerides).
Conclusions
Our data suggest that chemerin is a weak predictor of T2DM.
References
- 1Scarpellini, E. & Tack, J. (2012) Obesity and metabolic syndrome: an inflammatory condition. Digestive Diseases, 30, 148–153.
- 2Caspar-Bauguil, S., Cousin, B., Bour, S. et al. (2009) Adipose tissue lymphocytes: types and roles. Journal of Physiology and Biochemistry, 65, 423–436.
- 3Weisberg, S.P., McCann, D., Desai, M. et al. (2003) Obesity is associated with macrophage accumulation in adipose tissue. The Journal of Clinical Investigation, 112, 1796–1808.
- 4Anderson, E.K., Gutierrez, D.A. & Hasty, A.H. (2010) Adipose tissue recruitment of leukocytes. Current Opinion in Lipidology, 21, 172–177.
- 5Trayhurn, P. & Wood, I.S. (2005) Signalling role of adipose tissue: adipokines and inflammation in obesity. Biochemical Society Transactions, 33(Pt 5), 1078–1081.
- 6Kern, P.A., Ranganathan, S., Li, C. et al. (2001) Adipose tissue tumor necrosis factor and interleukin-6 expression in human obesity and insulin resistance. American Journal of Physiology. Endocrinology and Metabolism, 280, E745–E751.
- 7Cottam, D.R., Mattar, S.G., Barinas-Mitchell, E. et al. (2004) The chronic inflammatory hypothesis for the morbidity associated with morbid obesity: implications and effects of weight loss. Obesity Surgery, 14, 589–600.
- 8Nagpal, S., Patel, S., Jacobe, H. et al. (1997) Tazarotene-induced gene 2 (TIG2), a novel retinoid-responsive gene in skin. The Journal of Investigative Dermatology, 109, 91–95.
- 9Bozaoglu, K., Bolton, K., McMillan, J. et al. (2007) Chemerin is a novel adipokine associated with obesity and metabolic syndrome. Endocrinology, 148, 4687–4694.
- 10Wittamer, V., Franssen, J.D., Vulcano, M. et al. (2003) Specific recruitment of antigen-presenting cells by chemerin, a novel processed ligand from human inflammatory fluids. Journal of Experimental Medicine, 198, 977–985.
- 11Goralski, K.B., McCarthy, T.C., Hanniman, E.A. et al. (2007) Chemerin, a novel adipokine that regulates adipogenesis and adipocyte metabolism. Journal of Biological Chemistry, 282, 28175–28188.
- 12Zabel, B.A., Nakae, S., Zuniga, L. et al. (2008) Mast cell-expressed orphan receptor CCRL2 binds chemerin and is required for optimal induction of IgE-mediated passive cutaneous anaphylaxis. Journal of Experimental Medicine, 205, 2207–2220.
- 13Du, X.Y., Zabel, B.A., Myles, T. et al. (2009) Regulation of chemerin bioactivity by plasma carboxypeptidase N, carboxypeptidase B (activated thrombin-activable fibrinolysis inhibitor), and platelets. Journal of Biological Chemistry, 284, 751–758.
- 14Yang, M., Yang, G., Dong, J. et al. (2010) Elevated plasma levels of chemerin in newly diagnosed type 2 diabetes mellitus with hypertension. Journal of Investigative Medicine, 58, 883–886.
- 15Takahashi, M., Inomata, S., Okimura, Y. et al. (2013) Decreased serum chemerin levels in male Japanese patients with type 2 diabetes: sex dimorphism. Endocrine Journal, 60, 37–44.
- 16Chakaroun, R., Raschpichler, M., Kloting, N. et al. (2012) Effects of weight loss and exercise on chemerin serum concentrations and adipose tissue expression in human obesity. Metabolism, 61, 706–714.
- 17Sell, H., Divoux, A., Poitou, C. et al. (2010) Chemerin correlates with markers for fatty liver in morbidly obese patients and strongly decreases after weight loss induced by bariatric surgery. Journal of Clinical Endocrinology and Metabolism, 95, 2892–2896.
- 18Docke, S., Lock, J.F., Birkenfeld, A.L. et al. (2013) Elevated hepatic chemerin mRNA expression in human non-alcoholic fatty liver disease. European Journal of Endocrinology, 169, 547–557.
- 19Stejskal, D., Karpisek, M., Hanulova, Z. et al. (2008) Chemerin is an independent marker of the metabolic syndrome in a Caucasian population–a pilot study. Biomedical Papers of the Medical Faculty of the University Palacký, Olomouc, Czechoslovakia, 152, 217–221.
- 20Ouwens, D.M., Bekaert, M., Lapauw, B. et al. (2012) Chemerin as biomarker for insulin sensitivity in males without typical characteristics of metabolic syndrome. Archives of Physiology and Biochemistry, 118, 135–138.
- 21Weigert, J., Neumeier, M., Wanninger, J. et al. (2010) Systemic chemerin is related to inflammation rather than obesity in type 2 diabetes. Clinical Endocrinology (Oxford), 72, 342–348.
- 22Gu, P., Jiang, W., Lu, B. et al. (2014) Chemerin is associated with inflammatory markers and metabolic syndrome phenotypes in hypertension patients. Clinical and Experimental Hypertension, 36, 326–332.
- 23Guzel, E.C., Celik, C., Abali, R. et al. (2014) Omentin and chemerin and their association with obesity in women with polycystic ovary syndrome. Gynecological Endocrinology, 30, 419–422.
- 24Kim, S.H., Lee, S.H., Ahn, K.Y. et al. (2014) Effect of lifestyle modification on serum chemerin concentration and its association with insulin sensitivity in overweight and obese adults with type 2 diabetes. Clinical Endocrinology (Oxford), 80, 825–833.
- 25Neuparth, M.J., Proenca, J.B., Santos-Silva, A. et al. (2014) The positive effect of moderate walking exercise on chemerin levels in Portuguese patients with type 2 diabetes mellitus. Journal of Investigative Medicine, 62, 350–353.
- 26Spiroglou, S.G., Kostopoulos, C.G., Varakis, J.N. et al. (2010) Adipokines in periaortic and epicardial adipose tissue: differential expression and relation to atherosclerosis. Journal of Atherosclerosis and Thrombosis, 17, 115–130.
- 27Yoo, H.J., Choi, H.Y., Yang, S.J. et al. (2012) Circulating chemerin level is independently correlated with arterial stiffness. Journal of Atherosclerosis and Thrombosis, 19, 59–66.
- 28Lehrke, M., Becker, A., Greif, M. et al. (2009) Chemerin is associated with markers of inflammation and components of the metabolic syndrome but does not predict coronary atherosclerosis. European Journal of Endocrinology, 161, 339–344.
- 29Yan, Q., Zhang, Y., Hong, J. et al. (2012) The association of serum chemerin level with risk of coronary artery disease in Chinese adults. Endocrine, 41, 281–288.
- 30Dong, B., Ji, W. & Zhang, Y. (2011) Elevated serum chemerin levels are associated with the presence of coronary artery disease in patients with metabolic syndrome. Internal Medicine, 50, 1093–1097.
- 31Gao, X., Mi, S., Zhang, F. et al. (2011) Association of chemerin mRNA expression in human epicardial adipose tissue with coronary atherosclerosis. Cardiovascular Diabetology, 10, 87.
- 32Aronis, K.N., Sahin-Efe, A., Chamberland, J.P. et al. (2014) Chemerin levels as predictor of acute coronary events: a case-control study nested within the veterans affairs normative aging study. Metabolism, 63, 760–766.
- 33Ernst, M.C. & Sinal, C.J. (2010) Chemerin: at the crossroads of inflammation and obesity. Trends in Endocrinology and Metabolism, 21, 660–667.
- 34Bobbert, T., Schwarz, F., Fischer-Rosinsky, A. et al. (2013) Fibroblast growth factor 21 predicts the metabolic syndrome and type 2 diabetes in Caucasians. Diabetes Care, 36, 145–149.
- 35Fischer, A., Fisher, E., Mohlig, M. et al. (2008) KCNJ11 E23K affects diabetes risk and is associated with the disposition index: results of two independent German cohorts. Diabetes Care, 31, 87–89.
- 36Alberti, K.G. & Zimmet, P.Z. (1998) Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabetic Medicine, 15, 539–553.
10.1002/(SICI)1096-9136(199807)15:7<539::AID-DIA668>3.0.CO;2-S CAS PubMed Web of Science® Google Scholar
- 37Stumvoll, M., Mitrakou, A., Pimenta, W. et al. (2000) Use of the oral glucose tolerance test to assess insulin release and insulin sensitivity. Diabetes Care, 23, 295–301.
- 38Fischer-Rosinsky, A., Fisher, E., Kovacs, P. et al. (2008) Lack of association between the tagging SNP A + 930→G of SOCS3 and type 2 diabetes mellitus: meta-analysis of four independent study populations. PLoS ONE, 3, e3852.
- 39Takahashi, M., Takahashi, Y., Takahashi, K. et al. (2008) Chemerin enhances insulin signaling and potentiates insulin-stimulated glucose uptake in 3T3-L1 adipocytes. FEBS Letters, 582, 573–578.
- 40Kralisch, S., Weise, S., Sommer, G. et al. (2009) Interleukin-1beta induces the novel adipokine chemerin in adipocytes in vitro. Regulatory Peptides, 154, 102–106.
- 41Ernst, M.C., Issa, M., Goralski, K.B. et al. (2010) Chemerin exacerbates glucose intolerance in mouse models of obesity and diabetes. Endocrinology, 151, 1998–2007.
- 42Ernst, M.C., Haidl, I.D., Zuniga, L.A. et al. (2012) Disruption of the chemokine-like receptor-1 (CMKLR1) gene is associated with reduced adiposity and glucose intolerance. Endocrinology, 153, 672–682.
- 43Sell, H., Laurencikiene, J., Taube, A. et al. (2009) Chemerin is a novel adipocyte-derived factor inducing insulin resistance in primary human skeletal muscle cells. Diabetes, 58, 2731–2740.
- 44Becker, M., Rabe, K., Lebherz, C. et al. (2010) Expression of human chemerin induces insulin resistance in the skeletal muscle but does not affect weight, lipid levels, and atherosclerosis in LDL receptor knockout mice on high-fat diet. Diabetes, 59, 2898–2903.